132 related articles for article (PubMed ID: 37999452)
1. A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia.
Li R; Wang C; Ye Z; Chen Y; Xu J; Chen C; Yang J; Fu J; Zhou T; Zhou Z; Zhang X
Expert Rev Pharmacoecon Outcomes Res; 2023 Nov; ():1-8. PubMed ID: 37999452
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Kang DW; Wang L; Short NJ; Ferrajoli A; Wang Y; Zhou S; Shen C
Pharmacoeconomics; 2024 Apr; 42(4):409-418. PubMed ID: 38184494
[TBL] [Abstract][Full Text] [Related]
3. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
Zhou K; Wang T; Pan L; Xu W; Jin J; Zhang W; Hu Y; Hu J; Feng R; Li P; Liu Z; Liu P; Jing H; Gao S; Zhang H; Yu K; Wang Z; Zhu X; Sun Z; Li F; Yan D; Weng J; Fu L; Wang L; Salmi T; Wu K; Qiu L
Ann Hematol; 2024 Jun; ():. PubMed ID: 38888616
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.
Tam CS; Lamanna N; O'Brien SM; Qiu L; Yang K; Barnes G; Wu K; Salmi T; Brown JR
Curr Med Res Opin; 2023 Sep; ():1-7. PubMed ID: 37752892
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kaźmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang MD; Fu L; Li J; Wu K; Cohen A; Shadman M
N Engl J Med; 2023 Jan; 388(4):319-332. PubMed ID: 36511784
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients.
Nie J; Wu H; Wu Q; Liu Q; Liu L; Wu J
Future Oncol; 2023 Dec; 19(38):2525-2536. PubMed ID: 38059348
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.
Alrawashdh N; McBride A; Slack M; Persky D; Andritsos L; Abraham I
J Manag Care Spec Pharm; 2022 Apr; 28(4):390-400. PubMed ID: 35332792
[No Abstract] [Full Text] [Related]
8. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
[TBL] [Abstract][Full Text] [Related]
10. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
11. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
Barnes JI; Divi V; Begaye A; Wong R; Coutre S; Owens DK; Goldhaber-Fiebert JD
Blood Adv; 2018 Aug; 2(15):1946-1956. PubMed ID: 30097461
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Sinha R; Redekop WK
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran.
Fariman S; Momeni Nasab F; Faraji H; Afzali M
Value Health Reg Issues; 2023 Nov; 38():93-100. PubMed ID: 37806264
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine.
Mandrik O; Corro Ramos I; Knies S; Al M; Severens JL
Cancer Manag Res; 2015; 7():279-89. PubMed ID: 26345331
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China.
Li N; Zheng B; Cai H; Yang T; Hong Y; Liu M; Hu J
Support Care Cancer; 2022 Jul; 30(7):6113-6121. PubMed ID: 35419735
[TBL] [Abstract][Full Text] [Related]
19. Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia.
Hegde NC; Kumar A; Kaundal S; Saha L; Malhotra P; Prinja S; Lad D; Patil AN
Ann Hematol; 2023 Nov; 102(11):3125-3132. PubMed ID: 37439892
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.
Li H; Li G; Li N; Liu C; Yuan Z; Gao Q; Hao S; Fan S; Yang J
PLoS One; 2023; 18(11):e0291390. PubMed ID: 37971984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
